



an Open Access Journal by MDPI

Bryozoan Metabolites and Their Pharmacological Activities

Guest Editors:

Dr. Maria Letizia Ciavatta

National Research Council (CNR)
- Institute of Biomolecular
Chemistry (ICB), Pozzuoli, Italy

Dr. Marianna Carbone

National Research Council (CNR)
- Institute of Biomolecular
Chemistry (ICB), Pozzuoli, Italy

Deadline for manuscript
submissions:

closed (10 March 2022)

Message from the Guest Editors

Dear Colleagues,

The phylum Bryozoa comprises ~6000 described extant species from freshwater and marine environment. Despite this great biodiversity, the chemistry of this group has been poorly investigated in comparison with other invertebrates. Indeed, only 26 species have been investigated to date, revealing ca 300 molecules, indicating bryozoans as a rich source of novel chemical entities, only partially screened. In addition, most of the bryozoans compounds isolated so far, including the well-known bryostatins, have shown a wide spectra of pharmacological properties such as anticancer, antiparasitic, antiviral, and neurological activities, suggesting significant biomedical potential.

To increase interest in this underexplored group of organisms, the Special Issue “Bryozoan Metabolites and their Pharmacological Activities” will collect original papers, as well as reviews, focused on bryozoans natural product chemistry and bioactivity. Studies on bryozoans symbionts are welcome too.



mdpi.com/si/80239

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
[X@Marine_Drugs](#)